Major depressive disorder (MDD) afflicts millions globally, with conventional treatments often proving ineffective. This has fueled the exploration of unconventional therapeutic approaches. Among these, ketamine has emerged as a potential candidate for MDD treatment. Ketamine is a hallucinogenic age